C-Stem™ technology: Scaling-up iPS-derived cell therapy

$ 857.99
  • By A Mystery Man Writer
  • 5(136)
C-Stem™ technology: Scaling-up iPS-derived cell therapy

Product Description

TreeFrog Therapeutics has developed C-Stem, a technology allowing for the mass-production of iPS-derived cell therapies in large-scale bioreactors. C-stem is based on a proprietary high-throughput cell encapsulation technology which generates over 1,000 capsules per second. Each stem cell capsule constitutes a biomimetic micro-environment which recapitulates an in-vivo like stem cell niche. In the capsule, pluripotent stem cells self-organize to form an epiblast-like 3D stem cell microtissue which promotes exponential pluripotent stem cell growth, maintenance of homogenous pluripotency and high-fidelity chromosome segregation (preservation of genomic integrity). But the capsule is also protecting stem cells during manufacturing proceses. In fact, C-Stem allows for the scale-independent exponential amplification of hiPSCs and their differentiation into functional 3D microtissues in industrial bioreactors.

C-Stem™ technology: Scaling-up iPS-derived cell therapy

Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic

C-Stem™ technology: Scaling-up iPS-derived cell therapy

Generation and characterization of human induced pluripotent stem cells (iPSCs) from hand osteoarthritis patient-derived fibroblasts

C-Stem™ technology: Scaling-up iPS-derived cell therapy

Induced Pluripotent Stem Cells (iPSCs) for Cell Therapy

C-Stem™ technology: Scaling-up iPS-derived cell therapy

Definitive Endodermal Cells Supply an in vitro Source of Mesenchymal Stem/Stromal Cells

C-Stem™ technology: Scaling-up iPS-derived cell therapy

Skeletal muscle differentiation of human iPSCs meets bioengineering strategies: perspectives and challenges

C-Stem™ technology: Scaling-up iPS-derived cell therapy

A reference human induced pluripotent stem cell line for large-scale collaborative studies - ScienceDirect

C-Stem™ technology: Scaling-up iPS-derived cell therapy

Human pluripotent stem cell‐derived products: Advances towards robust, scalable and cost‐effective manufacturing strategies - Jenkins - 2015 - Biotechnology Journal - Wiley Online Library

C-Stem™ technology: Scaling-up iPS-derived cell therapy

Generation of Human iPSC-Derived Astrocytes with a mature star-shaped phenotype for CNS modeling

C-Stem™ technology: Scaling-up iPS-derived cell therapy

The Future of Regenerative Medicine: Cell Therapy Using Pluripotent Stem Cells and Acellular Therapies Based on Extracellular Vesicles. - Abstract - Europe PMC

C-Stem™ technology: Scaling-up iPS-derived cell therapy

Cells, Free Full-Text

C-Stem™ technology: Scaling-up iPS-derived cell therapy

PDF) A reference human induced pluripotent stem cell line for large-scale collaborative studies

C-Stem™ technology: Scaling-up iPS-derived cell therapy

Cell Proliferation, Cell Biology Journal

C-Stem™ technology: Scaling-up iPS-derived cell therapy

iPSC-derived Cell Therapy Development - Creative Biolabs